We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our
Cookie Policy
.
Accept
Label
Search
SKIP TO CONTENT
SKIP NAVIGATION
Drug Products
Books
FDAnews Books Library
Events
Form 483s Database
Subscription Newsletters
Free Newsletters
Webinar Training Pass
eCFR and Guidances
Device Products
Books
FDAnews Books Library
Events
Form 483s Database
Subscription Newsletters
Free Newsletters
Webinar Training Pass
eCFR and Guidances
Clinical Products
Advertising
White Papers
Contact Us
About Us
COVID-19
Sign In
Create Account
Sign Out
My Account
Home
» FDA Panel Backs Lung Infection Drug
FDA Panel Backs Lung Infection Drug
December 11, 2009
Federal health advisers are recommending the use of an experimental Gilead Sciences drug to treat a form of lung infection.
Concord Monitor
Upcoming Events
10
Mar
FDA Drug GMP Facility Inspections During the Pandemic
16
Mar
Pharmaceutical Naming Regulation: Understanding the Latest Developments
18
Mar
Pharmaceutical Postmarket Surveillance: Latest Developments in the Era of COVID-19
23
Mar
Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges
30
Mar
Data Integrity for GMP/Postmarket Professionals: Core Requirements, Expectations and Challenges
06
Apr
Medical Device Cybersecurity: Understand the Latest Developments
Featured Products
Biological Risk Evaluation and Management for Medical Devices
GMP Inspection Preparation Checklist: A Tool for Internal Auditing
Featured Stories
UK Study Says Single Shot of Pfizer/BioNTech Vaccine Significantly Lessened Asymptomatic Infections
Eurofins Receives FDA Emergency Authorization for Over-the-Counter COVID-19 Test
Vetex Medical’s Thrombectomy Catheter Cleared by FDA
Merck Purchases Rights to Debiopharm’s Xevinapant for More Than $1 Billion
The Revised ICH E8:
A Guide to New Clinical Trial Requirements
Learn More
